NDAORALSUSPENSION
Approved
Jan 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFATRIM (sulfamethoxazole and trimethoprim) by Inpharmus is cytochrome p450 2c9 inhibitors [moa]. First approved in 1983.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULFATRIM is an oral suspension containing sulfamethoxazole and trimethoprim, a combination sulfonamide antimicrobial approved in 1983. It treats prosthetic joint infections by inhibiting bacterial folate synthesis through dual mechanism of action. The drug blocks consecutive steps in nucleic acid and protein biosynthesis, making it bactericidal against susceptible organisms.
LOE Approaching
As an approaching LOE product with moderate competitive pressure (30), career opportunities are shifting from growth initiatives toward lifecycle extension, managed care negotiations, and transition planning.
Mechanism of Action
Cytochrome P450 2C9 Inhibitors
Pharmacologic Class:
Sulfonamide Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SULFATRIM offers limited career advancement due to zero linked job postings and LOE Approaching lifecycle status. Roles focus on defending market share against generics and managing payer relationships rather than growth-oriented activities.
Brand ManagerManaged Care Specialist
Worked on SULFATRIM at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.